Recent Finacing
Recent Raise
Affinivax develops MAPS-based vaccines that link polysaccharide and protein antigens to induce B‑ and T‑cell responses, advancing ASP3772 (24‑serotype pneumococcal) and other bacterial programs.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Affinivax.
